Victa Vinay Kumar
Research Subjects
Research Interests
Victa Vinay Kumar has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Graham Hill
Department of Surgery The University of Auckland Middlemore Hospital Auckland New Zealand
1 shared publication - Claudia Paterson
Department of Surgery The University of Auckland Auckland New Zealand
1 shared publication Vikash Sharma
Faculty of Internal Medicine Fiji National University Suva Fiji
1 shared publication
Latest Publications
- 23 June 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (9) , 1745-1749
Efficacy of ‘Triple Therapy’ in Eradicating Ulcer Related Helicobacter pylori Infection at a Tertiary Hospital in Fiji—A Pilot Study
Background: Fiji currently uses a seven‐day Clarithromycin based triple therapy regimen for Heliobacter pylori ( H. pylori ) eradication, and the local eradication rate is unknown. H. pylori testing is performed using a rapid urease test (RUT) during gastroscopy in Fiji. Methods: A year‐long prospective observational study was undertaken at the Colonial War Memorial Hospital in Fiji. Eligible participants included patients who had peptic ulcer disease (PUD) on gastroscopy and a positive RUT. Consenting participants were prescribed Clarithromycin based triple therapy for 7 days, and underwent a second gastroscopy with RUT after 6 to 8 weeks. Participants who tested positive on a repeat RUT received Clarithromycin based triple therapy for 14 days, and underwent a third gastroscopy and RUT. Participants who remained positive for H. pylori were prescribed quadruple therapy for 14 days. Results: Forty‐nine patients were enrolled in the study. Thirty‐six (73.5%) had a negative RUT after a seven‐day Clarithromycin‐based regimen. Eleven of the 13 participants who remained positive eradicated H. pylori after being given another course of the same regimen for 14 days, resulting in a final eradication rate of 95.9%. The remaining two participants received quadruple therapy for 14 days. Conclusion: This study demonstrates an eradication rate of 73.5% using a seven‐day Clarithromycin‐based regimen in Fiji among H. pylori positive patients with PUD on gastroscopy. This was significantly improved using a 14‐day regimen. H. pylori has reduced susceptibility to the current seven‐day Clarithromycin based regimen. Future local guidelines should extend to 14 days to achieve a greater eradication rate.
- 23 June 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (9) , 1745-1749
Efficacy of ‘Triple Therapy’ in Eradicating Ulcer Related Helicobacter pylori Infection at a Tertiary Hospital in Fiji—A Pilot Study
Background: Fiji currently uses a seven‐day Clarithromycin based triple therapy regimen for Heliobacter pylori ( H. pylori ) eradication, and the local eradication rate is unknown. H. pylori testing is performed using a rapid urease test (RUT) during gastroscopy in Fiji. Methods: A year‐long prospective observational study was undertaken at the Colonial War Memorial Hospital in Fiji. Eligible participants included patients who had peptic ulcer disease (PUD) on gastroscopy and a positive RUT. Consenting participants were prescribed Clarithromycin based triple therapy for 7 days, and underwent a second gastroscopy with RUT after 6 to 8 weeks. Participants who tested positive on a repeat RUT received Clarithromycin based triple therapy for 14 days, and underwent a third gastroscopy and RUT. Participants who remained positive for H. pylori were prescribed quadruple therapy for 14 days. Results: Forty‐nine patients were enrolled in the study. Thirty‐six (73.5%) had a negative RUT after a seven‐day Clarithromycin‐based regimen. Eleven of the 13 participants who remained positive eradicated H. pylori after being given another course of the same regimen for 14 days, resulting in a final eradication rate of 95.9%. The remaining two participants received quadruple therapy for 14 days. Conclusion: This study demonstrates an eradication rate of 73.5% using a seven‐day Clarithromycin‐based regimen in Fiji among H. pylori positive patients with PUD on gastroscopy. This was significantly improved using a 14‐day regimen. H. pylori has reduced susceptibility to the current seven‐day Clarithromycin based regimen. Future local guidelines should extend to 14 days to achieve a greater eradication rate.